ZALTRAP 25 mg/ml concentrate
ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Home | ziv-aflibercept solution
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
ZALTRAP 25 mg/ml concentrate
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer.
Zaltrap is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body) for whom treatment based on another medicine, oxaliplatin, has not worked or the cancer got worse. Zaltrap is used with FOLFIRI, which is a treatment combining the medicines irinotecan, 5-fluorouracil, and folinic acid. The medicine contains the active substance aflibercept. The European Commission granted a marketing authorisation valid throughout the European Union for Zaltrap on 1 February 2013.
Aflibercept (Eylea) is indicated for the treatment of people with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity. Aflibercept (Zaltrap), in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of people with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. It is used for the treatment of wet macular degeneration and is administered as an intravitreal injection, that is, into the eye. For cancer treatment, it is given intravenously in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI). In August 2014, aflibercept (Eylea) was approved for the treatment of people with visual impairment due to diabetic macular edema, according to the updated summary of product characteristics. In May 2019, the US FDA expanded the indication for aflibercept to include all stages of diabetic retinopathy. In February 2023, the US FDA approved aflibercept (Eylea) as a treatment for retinopathy of prematurity.
Drug (Brand / Generic): ZALTRAP / Ziv-Aflibercept
Current Indications: Colorectal Neoplasms
Marketed by:: Sanofi Winthrop Industrie
Approval Date: 01/02/2013
Available as (Form & Strength): 100 mg/4 mL (25 mg/mL) and 200 mg/8 mL (25 mg/mL).
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ZALTRAP 25 mg/ml concentrate for solution for infusion”.
Confirmation of the order for ZALTRAP 25 mg/ml concentrate will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand ZALTRAP 25 mg/ml concentrate. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to ZALTRAP 25 mg/ml concentrate, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for ZALTRAP 25 mg/ml concentrate price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.